STUDY ON SAFETY AND EFFECTIVENESS OF ORAL TOFACITINIB IN PATIENTS WITH REFRACTORY MODERATE TO SEVERE ATOPIC DERMATITIS

Abstract

Background: AD (atopic dermatitis) has a complicated etiology that includes Th2 polarization, which is related with the
cytokines IL-4, IL-5, and IL-13, as well as Th22, Th17, and Th1 cells in chronic lesions. Tofacitinib suppresses Th1, Th2, and
Th17 cytokines by preferentially inhibiting JAK3 and JAK1 receptors.
Aim: The current research sought to investigate the safety and effectiveness of oral tofacitinib in patients with refractory
moderate to severe atopic dermatitis.